AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-22-0241
Abstract: Abstract AZD4625 is a potent, selective, and orally bioavailable inhibitor of oncogenic KRASG12C as demonstrated in cellular assays and in vivo in preclinical cell line–derived and patient-derived xenograft models. In vitro and cellular assays have… read more here.
Keywords: inhibitor krasg12c; krasg12c; selective inhibitor; azd4625 potent ... See more keywords